EE04673B1 - Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid - Google Patents

Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE04673B1
EE04673B1 EEP200100010A EEP200100010A EE04673B1 EE 04673 B1 EE04673 B1 EE 04673B1 EE P200100010 A EEP200100010 A EE P200100010A EE P200100010 A EEP200100010 A EE P200100010A EE 04673 B1 EE04673 B1 EE 04673B1
Authority
EE
Estonia
Prior art keywords
pharmaceuticals
preparation
pharmaceutical compositions
compositions containing
quinoline derivatives
Prior art date
Application number
EEP200100010A
Other languages
English (en)
Estonian (et)
Inventor
Bj�rk Anders
J�nsson Stig
Fex Tomas
Hedlund Gunnar
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of EE200100010A publication Critical patent/EE200100010A/xx
Publication of EE04673B1 publication Critical patent/EE04673B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100010A 1998-07-15 1999-07-14 Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid EE04673B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives
PCT/SE1999/001270 WO2000003991A1 (en) 1998-07-15 1999-07-14 Quinoline derivatives

Publications (2)

Publication Number Publication Date
EE200100010A EE200100010A (et) 2002-06-17
EE04673B1 true EE04673B1 (et) 2006-08-15

Family

ID=20412093

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100010A EE04673B1 (et) 1998-07-15 1999-07-14 Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid

Country Status (32)

Country Link
EP (1) EP1095021B1 (cs)
JP (1) JP4045070B2 (cs)
KR (1) KR100516382B1 (cs)
CN (1) CN1157378C (cs)
AP (1) AP1366A (cs)
AT (1) ATE250036T1 (cs)
AU (1) AU751103B2 (cs)
BR (1) BR9912109B1 (cs)
CA (1) CA2336968C (cs)
CZ (1) CZ300229B6 (cs)
DE (1) DE69911415T2 (cs)
DK (1) DK1095021T3 (cs)
EE (1) EE04673B1 (cs)
ES (1) ES2205854T3 (cs)
HR (1) HRP20010039B1 (cs)
HU (1) HU229427B1 (cs)
ID (1) ID27423A (cs)
IL (2) IL140346A0 (cs)
IS (1) IS2208B (cs)
ME (1) MEP57408A (cs)
NO (1) NO317601B1 (cs)
NZ (1) NZ508923A (cs)
OA (1) OA11906A (cs)
PL (1) PL199783B1 (cs)
PT (1) PT1095021E (cs)
RS (1) RS50128B (cs)
RU (1) RU2213733C2 (cs)
SE (1) SE9802549D0 (cs)
TR (1) TR200100087T2 (cs)
UA (1) UA64791C2 (cs)
WO (1) WO2000003991A1 (cs)
ZA (1) ZA200007593B (cs)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
EP1512396A4 (en) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
CN1658855B (zh) 2002-06-06 2010-04-28 株式会社医药分子设计研究所 O-取代羟基芳基衍生物
EA011707B1 (ru) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
EP2687512A1 (en) 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
ATE532515T1 (de) 2006-06-12 2011-11-15 Teva Pharma Stabile laquinimod-zubereitungen
WO2008113006A1 (en) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
ES2633658T3 (es) 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
MX2012001333A (es) 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
KR20150135552A (ko) 2010-03-03 2015-12-02 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
EP2542079B1 (en) 2010-03-03 2014-05-21 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
CA2804986A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
ES2537615T3 (es) * 2010-08-27 2015-06-10 Grünenthal GmbH 2-Oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidas como moduladores de KCNQ2/3
US8962598B2 (en) * 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
SG11201404214QA (en) 2012-02-03 2014-08-28 Teva Pharma USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
BR112014020372A8 (pt) 2012-02-16 2018-01-23 Teva Pharma n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
JP5868839B2 (ja) 2012-12-27 2016-02-24 三菱重工業株式会社 チャー払出管
CN105051013A (zh) 2013-03-14 2015-11-11 泰华制药工业有限公司 拉喹莫德钠晶体及其改进的制造方法
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN105367492B (zh) * 2014-08-28 2018-07-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
EA030948B1 (ru) 2014-09-23 2018-10-31 Эктив Байотек Аб Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX379401B (es) 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) * 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
ES3032708T3 (en) 2020-03-03 2025-07-23 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
JP7747732B2 (ja) 2020-07-23 2025-10-01 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質
MX2023008016A (es) 2021-01-18 2023-07-13 Active Biotech Ab Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
CA3218977A1 (en) 2021-05-25 2022-12-01 Hans Wannman A plurality of tasquinimod particles and use thereof
WO2023275248A1 (en) 2021-07-02 2023-01-05 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
AR126963A1 (es) * 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) * 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
JPH07224040A (ja) * 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
HUP0103224A3 (en) 2002-11-28
OA11906A (en) 2006-04-10
NO20010211L (no) 2001-03-15
CN1309641A (zh) 2001-08-22
AU4950499A (en) 2000-02-07
ME00374B (me) 2011-05-10
HUP0103224A2 (hu) 2002-01-28
NO317601B1 (no) 2004-11-22
IL140346A (en) 2006-07-05
CZ200194A3 (en) 2001-05-16
RU2213733C2 (ru) 2003-10-10
BR9912109A (pt) 2001-05-02
JP4045070B2 (ja) 2008-02-13
HU229427B1 (en) 2013-12-30
NO20010211D0 (no) 2001-01-12
DE69911415D1 (de) 2003-10-23
HK1035715A1 (en) 2001-12-07
BR9912109B1 (pt) 2012-08-21
HRP20010039A2 (en) 2001-12-31
DE69911415T2 (de) 2004-07-08
AP1366A (en) 2005-01-26
WO2000003991A1 (en) 2000-01-27
NZ508923A (en) 2002-09-27
AP2001002041A0 (en) 2001-03-31
CA2336968C (en) 2005-08-30
EP1095021A1 (en) 2001-05-02
IL140346A0 (en) 2002-02-10
EP1095021B1 (en) 2003-09-17
HRP20010039B1 (en) 2009-04-30
UA64791C2 (en) 2004-03-15
CA2336968A1 (en) 2000-01-27
YU1501A (sh) 2003-10-31
CN1157378C (zh) 2004-07-14
AU751103B2 (en) 2002-08-08
EE200100010A (et) 2002-06-17
RS50128B (sr) 2009-03-25
MEP57408A (en) 2011-05-10
DK1095021T3 (da) 2003-11-24
IS2208B (is) 2007-02-15
ES2205854T3 (es) 2004-05-01
CZ300229B6 (cs) 2009-03-25
KR20010053115A (ko) 2001-06-25
ATE250036T1 (de) 2003-10-15
ZA200007593B (en) 2001-07-09
TR200100087T2 (tr) 2001-06-21
JP2002520395A (ja) 2002-07-09
KR100516382B1 (ko) 2005-09-26
PT1095021E (pt) 2003-12-31
PL345388A1 (en) 2001-12-17
IS5775A (is) 2000-12-18
PL199783B1 (pl) 2008-10-31
SE9802549D0 (sv) 1998-07-15
ID27423A (id) 2001-04-05

Similar Documents

Publication Publication Date Title
EE04673B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE04276B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200300046A (et) Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE200200138A (et) Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
EE200200065A (et) 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
EE200000707A (et) Oksasolidinooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200300126A (et) Kinoliini ja kinolinooni derivaadid glutamaatretseptori antagonistidena, nende saamine ja kasutamine ravimite valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EE04779B1 (et) 1,3-dihüdro-2H-indool-2-ooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE05034B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende valmistamise meetodid
EE200300080A (et) Polüarüülkarboksamiidühendid, nende valmistamine ja kasutamine lipiiditaset alandavate toimeainetena ning neid sisaldav farmatseutiline kompositsioon
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
EE200000791A (et) Uudsed atsüülpseudopeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200200149A (et) Kinasoliinühendid ja neid sisaldavad ravimkoostised
EE04343B1 (et) Pürasoolkarboksüülhappe derivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE04679B1 (et) Tuumorivastase toimega kamptotetsiini derivaadid,meetod nende valmistamiseks ja neid hendeid sisaldavad farmatseutilised kompositsioonid
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200100529A (et) Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE200000429A (et) Sünteetilised polüsahhariidid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE200300574A (et) Aminokinoliini derivaadid, nende valmistamine, neid sisaldavad ravimkoostised ja nende kasutamine adenosiini A3-retseptori ligandidena
EE9800069A (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
EE05004B1 (et) Aminotiasooli derivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200200292A (et) Asendatud norbornüülaminoderivaadid, nende valmistamine ja kasutamine ravimitena või diagnostilisteainetena ning neid sisaldav ravim

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231